MX368496B - Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. - Google Patents
Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.Info
- Publication number
- MX368496B MX368496B MX2016013265A MX2016013265A MX368496B MX 368496 B MX368496 B MX 368496B MX 2016013265 A MX2016013265 A MX 2016013265A MX 2016013265 A MX2016013265 A MX 2016013265A MX 368496 B MX368496 B MX 368496B
- Authority
- MX
- Mexico
- Prior art keywords
- pyrazolo
- analogues
- parp inhibitors
- benzimidazole compound
- compound
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title abstract 3
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title abstract 3
- -1 of 4h-pyrazolo[1,5-a]benzimidazole compound Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se da a conocer una serie de análogos del compuesto 4H-pirazolo[1,5-?]bencimidazol como inhibidores de PARP; en particular, se describe en la invención un compuesto tal como se muestra por la fórmula (I) o una sal farmacéuticamente aceptable del mismo como un inhibidor de PARP.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144173.0A CN104974161B (zh) | 2014-04-10 | 2014-04-10 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| CN201510113090 | 2015-03-13 | ||
| PCT/CN2015/075363 WO2015154630A1 (zh) | 2014-04-10 | 2015-03-30 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016013265A MX2016013265A (es) | 2017-05-03 |
| MX368496B true MX368496B (es) | 2019-10-04 |
Family
ID=54287319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013265A MX368496B (es) | 2014-04-10 | 2015-03-30 | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9856262B2 (es) |
| EP (1) | EP3130592B1 (es) |
| JP (1) | JP6359175B2 (es) |
| KR (1) | KR101921486B1 (es) |
| CN (1) | CN106459057B (es) |
| AU (1) | AU2015245786B2 (es) |
| BR (1) | BR112016023397B1 (es) |
| CA (1) | CA2944801C (es) |
| DK (1) | DK3130592T3 (es) |
| ES (1) | ES2754590T3 (es) |
| HU (1) | HUE047410T2 (es) |
| IL (1) | IL248258B (es) |
| MX (1) | MX368496B (es) |
| NZ (1) | NZ725165A (es) |
| PL (1) | PL3130592T3 (es) |
| PT (1) | PT3130592T (es) |
| RU (1) | RU2672722C2 (es) |
| SA (1) | SA516380051B1 (es) |
| SG (1) | SG11201608438YA (es) |
| TW (1) | TWI671301B (es) |
| WO (1) | WO2015154630A1 (es) |
| ZA (1) | ZA201607736B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974161B (zh) * | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
| TWI716463B (zh) * | 2015-09-30 | 2021-01-21 | 大陸商湖北生物醫藥產業技術研究院有限公司 | 4H-吡唑並[1,5-a]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CA3061406A1 (en) | 2017-04-27 | 2018-11-01 | Bayer Animal Health Gmbh | New bicyclic pyrazole derivatives |
| CN115028641B (zh) * | 2022-07-19 | 2024-05-28 | 湖南大学 | 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025056690A1 (en) | 2023-09-12 | 2025-03-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Parp1- and immune-checkpoint inhibitors for the treatment of cancer patients overexpressing ubqln1 and/or ubqln4 |
| CN116969954B (zh) * | 2023-09-21 | 2023-11-28 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含内酰胺的三环稠合杂环化合物及其应用 |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| CN117534677B (zh) * | 2024-01-09 | 2024-03-12 | 广东省农业科学院农业质量标准与监测技术研究所 | 一类含亚胺的三环稠合杂环化合物及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916051A (en) * | 1987-04-07 | 1990-04-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| AR046967A1 (es) * | 2003-12-22 | 2006-01-04 | Sb Pharmco Inc | Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
| EP1973909A2 (en) | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
| WO2007144669A1 (en) * | 2006-06-15 | 2007-12-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp) |
| ES2559679T3 (es) * | 2006-06-20 | 2016-02-15 | Abbvie Inc. | Pirazoloquinazolinonas como inhibidores de PARP |
| GB0701273D0 (en) * | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| DK2656843T3 (en) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
| SG11201406997WA (en) * | 2012-05-04 | 2014-11-27 | Merck Patent Gmbh | Pyrrolotriazinone derivatives |
| EP2666775A1 (en) | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| KR20150005711A (ko) | 2012-06-07 | 2015-01-14 | 에프. 호프만-라 로슈 아게 | 탄키라제 억제제로서 피롤로피리미돈 및 피롤로피리돈 |
| IN2015MN00002A (es) * | 2012-07-09 | 2015-10-16 | Lupin Ltd | |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| DK2882714T3 (da) * | 2012-08-08 | 2020-01-20 | Merck Patent Gmbh | (aza-)isoquinolinonderivater |
| CN104974161B (zh) | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物 |
-
2015
- 2015-03-30 AU AU2015245786A patent/AU2015245786B2/en active Active
- 2015-03-30 US US15/302,588 patent/US9856262B2/en active Active
- 2015-03-30 HU HUE15777444A patent/HUE047410T2/hu unknown
- 2015-03-30 BR BR112016023397-2A patent/BR112016023397B1/pt active IP Right Grant
- 2015-03-30 CN CN201580017657.1A patent/CN106459057B/zh active Active
- 2015-03-30 RU RU2016144202A patent/RU2672722C2/ru active
- 2015-03-30 WO PCT/CN2015/075363 patent/WO2015154630A1/zh not_active Ceased
- 2015-03-30 CA CA2944801A patent/CA2944801C/en active Active
- 2015-03-30 PT PT157774449T patent/PT3130592T/pt unknown
- 2015-03-30 SG SG11201608438YA patent/SG11201608438YA/en unknown
- 2015-03-30 ES ES15777444T patent/ES2754590T3/es active Active
- 2015-03-30 EP EP15777444.9A patent/EP3130592B1/en active Active
- 2015-03-30 MX MX2016013265A patent/MX368496B/es active IP Right Grant
- 2015-03-30 KR KR1020167031520A patent/KR101921486B1/ko active Active
- 2015-03-30 DK DK15777444T patent/DK3130592T3/da active
- 2015-03-30 PL PL15777444T patent/PL3130592T3/pl unknown
- 2015-03-30 NZ NZ725165A patent/NZ725165A/en unknown
- 2015-03-30 JP JP2017504223A patent/JP6359175B2/ja active Active
- 2015-04-08 TW TW104111236A patent/TWI671301B/zh active
-
2016
- 2016-10-09 IL IL248258A patent/IL248258B/en active IP Right Grant
- 2016-10-10 SA SA516380051A patent/SA516380051B1/ar unknown
- 2016-11-09 ZA ZA2016/07736A patent/ZA201607736B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016013265A (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| MY189557A (en) | Pyridone compound as c-met inhibitor | |
| SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| JO3318B1 (ar) | مثبطات bace | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| TW201613898A (en) | Benzofuran analogue as NS4B inhibitor | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| JO3298B1 (ar) | مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt | |
| TW201613928A (en) | Vinyl compounds as inhibitors for FGFR and VEGFR | |
| MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: HUMANWELL HEALTHCARE (GROUP) CO., LTD. |
|
| FG | Grant or registration |